These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38588523)

  • 1. Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials.
    MacIsaac S; Somboonviboon D; Scallan C; Kolb M
    Expert Opin Emerg Drugs; 2024 Jun; 29(2):177-186. PubMed ID: 38588523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of α
    Decaris ML; Schaub JR; Chen C; Cha J; Lee GG; Rexhepaj M; Ho SS; Rao V; Marlow MM; Kotak P; Budi EH; Hooi L; Wu J; Fridlib M; Martin SP; Huang S; Chen M; Muñoz M; Hom TF; Wolters PJ; Desai TJ; Rock F; Leftheris K; Morgans DJ; Lepist EI; Andre P; Lefebvre EA; Turner SM
    Respir Res; 2021 Oct; 22(1):265. PubMed ID: 34666752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targets and early stage clinical trials for pulmonary fibrosis.
    Sato S; Yanagihara T; Kolb MRJ
    Expert Opin Investig Drugs; 2019 Jan; 28(1):19-28. PubMed ID: 30513000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options.
    Trachalaki A; Irfan M; Wells AU
    Expert Opin Pharmacother; 2021 Feb; 22(2):191-204. PubMed ID: 32993388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis.
    Bellani S; Molyneaux PL; Maher TM; Spagnolo P
    Expert Opin Ther Targets; 2024 Jul; ():1-11. PubMed ID: 38949181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
    Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising advances in treatments for the management of idiopathic pulmonary fibrosis.
    Sofia C; Comes A; Sgalla G; Richeldi L
    Expert Opin Pharmacother; 2024 Apr; 25(6):717-725. PubMed ID: 38832823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on current and emerging drug treatments for idiopathic pulmonary fibrosis.
    Trachalaki A; Sultana N; Wells AU
    Expert Opin Pharmacother; 2023; 24(10):1125-1142. PubMed ID: 37183672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials.
    Sgalla G; Lerede M; Richeldi L
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):93-101. PubMed ID: 33998354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib for Idiopathic Pulmonary Fibrosis.
    Tepede A; Yogaratnam D
    J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA
    Corte TJ; Lancaster L; Swigris JJ; Maher TM; Goldin JG; Palmer SM; Suda T; Ogura T; Minnich A; Zhan X; Tirucherai GS; Elpers B; Xiao H; Watanabe H; Smith RA; Charles ED; Fischer A
    BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34969771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond.
    Sofia C; Comes A; Sgalla G; Richeldi L
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):283-296. PubMed ID: 37953604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
    Aryal S; Nathan SD
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LPA
    Decato BE; Leeming DJ; Sand JMB; Fischer A; Du S; Palmer SM; Karsdal M; Luo Y; Minnich A
    Respir Res; 2022 Mar; 23(1):61. PubMed ID: 35303880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF).
    Sgalla G; Simonetti J; Cortese S; Richeldi L
    Expert Opin Investig Drugs; 2023 Jan; 32(1):17-23. PubMed ID: 36693635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shedding light on developmental drugs for idiopathic pulmonary fibrosis.
    Spagnolo P; Bonella F; Ryerson CJ; Tzouvelekis A; Maher TM
    Expert Opin Investig Drugs; 2020 Aug; 29(8):797-808. PubMed ID: 32538186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.